Tocilizumab for the Treatment of Behçet Uveitis that Failed Interferon Alpha and Anti-Tumor Necrosis Factor-Alpha Therapy

REFERENCES

• Tugal-Tutkun I, Gupta V, Cunningham ET. Differential diagnosis of Behcet uveitis. Ocul Immunol Inflamm. 2013;21(5):337–350.
   PubMed Web of Science ®Google Scholar
• Tugal-Tutkun I, Onal S, Altan-Yaycioglu R, et al. Uveitis in Behcet disease: an analysis of 880 patients. Am J Ophthalmol. 2004;138(3):373–380.
   PubMed Web of Science ®Google Scholar
• Zierhut M, Abu El-Asrar AM, Bodaghi B, et al. Therapy of ocular Behcet disease. Ocul Immunol Inflamm. 2014;22(1):64–76.
   PubMed Web of Science ®Google Scholar
• Cantarini L, Vitale A, Scalini P, et al. Anakinra treatment in drug-resistant Behcet’s disease: a case series. Clin Rheumatol. 2015;34(7):1293–1301.
   PubMed Web of Science ®Google Scholar
• Ugurlu S, Ucar D, Seyahi E, et al. Canakinumab in a patient with juvenile Behcet’s syndrome with refractory eye disease. Ann Rheum Dis. 2012;71(9):1589–1591.
   PubMed Web of Science ®Google Scholar
• Gul A, Tugal-Tutkun I, Dinarello CA, et al. Interleukin-1beta-regulating antibody XOMA 052 (gevokizumab) in the treatment of acute exacerbations of resistant uveitis of Behcet’s disease: an open-label pilot study. Ann Rheum Dis. 2012;71(4):563–566.
   PubMed Web of Science ®Google Scholar
• Hirano T, Ohguro N, Hohki S, et al. A case of Behcet’s disease treated with a humanized anti-interleukin-6 receptor antibody, tocilizumab. Mod Rheumatol. 2012;22(2):298–302.
   PubMed Web of Science ®Google Scholar
• Deroux A, Chiquet C, Bouillet L, Tocilizumab in severe and refractory Behcet’s disease: four cases and literature review. Semin Arthritis Rheum. 2016;45(6):733–737.
   PubMed Web of Science ®Google Scholar
• Tappeiner C, Heinz C, Ganser G, et al. Is tocilizumab an effective option for treatment of refractory uveitis associated with juvenile idiopathic arthritis? J Rheumatol. 2012;39(6):1294–1295.
   PubMed Web of Science ®Google Scholar
• Adan A, Mesquida M, Llorenc V, et al. Tocilizumab treatment for refractory uveitis-related cystoid macular edema. Graefes Arch Clin Exp Ophthalmol. 2013;251(11):2627–2632.
   PubMed Web of Science ®Google Scholar
• Tsang AC, Roth J, Gottlieb C, Tocilizumab for severe chronic anterior uveitis associated with juvenile idiopathic arthritis in a pediatric patient. Ocul Immunol Inflamm. 2014;22(2):155–157.
   PubMed Web of Science ®Google Scholar
• Papo M, Bielefeld P, Vallet H, et al. Tocilizumab in severe and refractory non-infectious uveitis. Clin Exp Rheumatol. 2014;32(4 Suppl 84):S75–S79.
   PubMed Web of Science ®Google Scholar
• Mesquida M, Molins B, Llorenc V, et al. Long-term effects of tocilizumab therapy for refractory uveitis-related macular edema. Ophthalmology. 2014;121(12):2380–2386.
   PubMed Web of Science ®Google Scholar
• Silpa-Archa S, Oray M, Preble JM, et al. Outcome of tocilizumab treatment in refractory ocular inflammatory diseases. Acta Ophthalmologica. 2016;94(6):e400–406.
   PubMed Web of Science ®Google Scholar
• Criteria for diagnosis of Behcet’s disease. International study group for Behcet’s disease. Lancet. 1990;335(8697):1078–1080.
   PubMed Web of Science ®Google Scholar
• Jabs DA, Nussenblatt RB, Rosenbaum JT, et al. Standardization of uveitis nomenclature for reporting clinical data. Results of the first international workshop. Am J Ophthalmol. 2005;140(3):509–516.
   PubMed Web of Science ®Google Scholar
• Tugal-Tutkun I, Herbort CP, Khairallah M, et al. Scoring of dual fluorescein and ICG inflammatory angiographic signs for the grading of posterior segment inflammation (dual fluorescein and ICG angiographic scoring system for uveitis). International Ophthalmology. 2010;30(5):539–552.
   PubMedGoogle Scholar
• Kimura A, Kishimoto T, IL-6: regulator of Treg/Th17 balance. Eur J Immunol. 2010;40(7):1830–1835.
   PubMed Web of Science ®Google Scholar
• Yoshimura T, Sonoda KH, Ohguro N, et al. Involvement of Th17 cells and the effect of anti-IL-6 therapy in autoimmune uveitis. Rheumatology (Oxford). 2009;48(4):347–354.
   PubMed Web of Science ®Google Scholar
• Perez VL, Papaliodis GN, Chu D, et al. Elevated levels of interleukin 6 in the vitreous fluid of patients with pars planitis and posterior uveitis: the Massachusetts eye & ear experience and review of previous studies. Ocul Immunol Inflamm. 2004;12(3):193–201.
   PubMed Web of Science ®Google Scholar
• Deuter CM, Zierhut M, Igney-Oertel A, et al. Tocilizumab in uveitic macular edema refractory to previous immunomodulatory treatment. Ocul Immunol Inflamm. 2016;1–6. doi:10.3109/09273948.2015.1099680. [Epub ahead of print]
   Web of Science ®Google Scholar
• Tugal-Tutkun I, Cingu K, Kir N, et al. Use of laser flare-cell photometry to quantify intraocular inflammation in patients with Behcet uveitis. Graefes Arch Clin Exp Ophthalmol. 2008;246(8):1169–1177.
   PubMed Web of Science ®Google Scholar
• Onal S, Uludag G, Oray M, et al. Quantitative analysis of structural alterations in the choroid of patients with active Behcet uveitis. Retina. 2017. doi:10.1097/IAE.0000000000001587. [Epub ahead of print]
   PubMed Web of Science ®Google Scholar
• Smolen JS, Landewe R, Bijlsma J, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. Ann Rheum Dis. 2017. doi:10.1136/annrheumdis-2016-210715. [Epub ahead of print]
   Web of Science ®Google Scholar
• Calvo-Rio V, De La Hera D, Beltran-Catalan E, et al. Tocilizumab in uveitis refractory to other biologic drugs: a study of 3 cases and a literature review. Clin Exp Rheumatol. 2014;32(4 Suppl 84):S54–S57.
   PubMed Web of Science ®Google Scholar
• Santos-Gomez M, Calvo-Rio V, Blanco R, et al. The effect of biologic therapy different from infliximab or adalimumab in patients with refractory uveitis due to Behcet’s disease: results of a multicentre open-label study. Clin Exp Rheumatol. 2016; 34 Suppl 102(6):34–40.
   Google Scholar
• Addimanda O, Pipitone N, Pazzola G, et al. Tocilizumab for severe refractory neuro-Behcet: three cases IL-6 blockade in neuro-Behcet. Semin Arthritis Rheum. 2015;44(4):472–475.
   PubMed Web of Science ®Google Scholar
• Shapiro LS, Farrell J, Borhani Haghighi A, Tocilizumab treatment for neuro-Behcet’s disease, the first report. Clin Neurol Neurosurg. 2012;114(3):297–298.
   PubMed Web of Science ®Google Scholar
• Borhani Haghighi A, Safari A, Tocilizumab may be a potential addition to our weapons against neuro-Behcet’s disease. Med Hypotheses. 2008;71(1):156–157.
   PubMed Web of Science ®Google Scholar
• Borhani Haghighi A, Ittehadi H, Nikseresht AR, et al. CSF levels of cytokines in neuro-Behcet’s disease. Clin Neurol Neurosurg. 2009;111(6):507–510.
   PubMed Web of Science ®Google Scholar
• Akman-Demir G, Tuzun E, Icoz S, et al. Interleukin-6 in neuro-Behcet’s disease: association with disease subsets and long-term outcome. Cytokine. 2008;44(3):373–376.
   PubMed Web of Science ®Google Scholar
• Emmi G, Silvestri E, Squatrito D, et al. Tocilizumab-induced exacerbation of mucosal ulcers in a patient with multi-refractory Behcet’s disease. Semin Arthritis Rheum. 2016;46(1):e1–e2.
   PubMedGoogle Scholar
• Cantarini L, Lopalco G, Vitale A, et al. Paradoxical mucocutaneous flare in a case of Behcet’s disease treated with tocilizumab. Clin Rheumatol. 2015;34(6):1141–1143.
   PubMed Web of Science ®Google Scholar
• Diamantopoulos AP, Hatemi G, Lack of efficacy of tocilizumab in mucocutaneous Behcet’s syndrome: report of two cases. Rheumatology (Oxford). 2013;52(10):1923–1924.
   PubMed Web of Science ®Google Scholar
• Bijlsma JW, Welsing PM, Woodworth TG, et al. Early rheumatoid arthritis treated with tocilizumab, methotrexate, or their combination (U-Act-Early): a multicentre, randomised, double-blind, double-dummy, strategy trial. Lancet. 2016;388(10042):343–355.
   PubMed Web of Science ®Google Scholar